drugset / Trial / NCT06643884
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Timeline
- Start
- 2024-12-16
- Primary completion
- 2026-11-30
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 40 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 80 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 140 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 200 ug | Other |